ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition in metastatic urothelial carcinoma: a systematic review and meta-analysis.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) are standard components of metastatic urothelial carcinoma (mUC) treatment, but the association between FGFR3 alteration status and ICI outcomes remains uncertain.
methodsThe protocol was prospectively registered in PROSPERO (CRD420251114235). PubMed/MEDLINE, Scopus, and Embase were searched from inception through 22 November 2025; reference lists of included studies and relevant reviews were also examined. Eligible studies compared adults with FGFR3-altered versus FGFR3-wild-type mUC treated with PD-1, PD-L1, and/or CTLA-4 inhibitors. Random effects models pooled risk ratios (RRs) for objective response rate (ORR) and disease control rate (DCR), and hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS). Risk of bias was evaluated using RoB 2 and the Newcastle-Ottawa scale as appropriate. Leave-one-out analyses were performed for all endpoints; small-study effects were assessed for OS at the publication level.
results13 publications met the eligibility criteria, and 12 contributed to at least one quantitative synthesis. The largest endpoint analysis, OS, included 13 cohort-level comparisons from 11 publications and 2042 patients. FGFR3 alterations were associated with lower DCR (RR 0.74, 95% CI 0.57-0.96; I
conclusionsAmongst patients treated with ICIs, FGFR3 alterations were associated with less Disease Control and shorter time-to-event outcomes, whilst ORR was not significantly different. Because the evidence is predominantly retrospective or derived from exploratory biomarker subgroups and lacks a non-ICI comparator, these findings do not establish a predictive treatment interaction or causal immunotherapy resistance. They should be regarded as hypothesis-generating and support prospective biomarker-stratified validation, including trials evaluating FGFR inhibition with immunotherapy.
Indexed as
Identifiers
42717171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.